1 Report Overview

• 1.1 Study Scope
• 1.2 Market Analysis by Type
• 1.2.1 Global Ulcerative Colitis Medicine Market Size Growth Rate by Type: 2017 VS 2021 VS 2028

1.2.2 5-Aminosalicylic Acid

1.2.3 Corticosteroids

1.2.4 Immunomodulator Drugs

1.2.5 Biologics

1.3 Market by Application

1.3.1 Global Ulcerative Colitis Medicine Market Share by Application: 2017 VS 2021 VS 2028

1.3.2 Ulcerative Proctitis

1.3.3 Proctosigmoiditis

1.3.4 Left-Sided Colitis

1.3.5 Pancolitis

1.3.6 Acute Severe Ulcerative Colitis

1.4 Study Objectives

1.5 Years Considered

2 Global Growth Trends

• 2.1 Global Ulcerative Colitis Medicine Market Perspective (2017-2028)
• 2.2 Ulcerative Colitis Medicine Growth Trends by Region
• 2.2.1 Ulcerative Colitis Medicine Market Size by Region: 2017 VS 2021 VS 2028

2.2.2 Ulcerative Colitis Medicine Historic Market Size by Region (2017-2022)

2.2.3 Ulcerative Colitis Medicine Forecasted Market Size by Region (2023-2028)

2.3 Ulcerative Colitis Medicine Market Dynamics

2.3.1 Ulcerative Colitis Medicine Industry Trends

2.3.2 Ulcerative Colitis Medicine Market Drivers

2.3.3 Ulcerative Colitis Medicine Market Challenges

2.3.4 Ulcerative Colitis Medicine Market Restraints

3 Competition Landscape by Key Players

• 3.1 Global Top Ulcerative Colitis Medicine Players by Revenue
• 3.1.1 Global Top Ulcerative Colitis Medicine Players by Revenue (2017-2022)

3.1.2 Global Ulcerative Colitis Medicine Revenue Market Share by Players (2017-2022)

3.2 Global Ulcerative Colitis Medicine Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Players Covered: Ranking by Ulcerative Colitis Medicine Revenue

3.4 Global Ulcerative Colitis Medicine Market Concentration Ratio

3.4.1 Global Ulcerative Colitis Medicine Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Ulcerative Colitis Medicine Revenue in 2021

3.5 Ulcerative Colitis Medicine Key Players Head office and Area Served

3.6 Key Players Ulcerative Colitis Medicine Product Solution and Service

3.7 Date of Enter into Ulcerative Colitis Medicine Market

3.8 Mergers & Acquisitions, Expansion Plans

4 Ulcerative Colitis Medicine Breakdown Data by Type

• 4.1 Global Ulcerative Colitis Medicine Historic Market Size by Type (2017-2022)
• 4.2 Global Ulcerative Colitis Medicine Forecasted Market Size by Type (2023-2028)

5 Ulcerative Colitis Medicine Breakdown Data by Application

• 5.1 Global Ulcerative Colitis Medicine Historic Market Size by Application (2017-2022)
• 5.2 Global Ulcerative Colitis Medicine Forecasted Market Size by Application (2023-2028)

6 North America

• 6.1 North America Ulcerative Colitis Medicine Market Size (2017-2028)
• 6.2 North America Ulcerative Colitis Medicine Market Size by Country (2017-2022)
• 6.3 North America Ulcerative Colitis Medicine Market Size by Country (2023-2028)
• 6.4 United States
• 6.5 Canada

7 Europe

• 7.1 Europe Ulcerative Colitis Medicine Market Size (2017-2028)
• 7.2 Europe Ulcerative Colitis Medicine Market Size by Country (2017-2022)
• 7.3 Europe Ulcerative Colitis Medicine Market Size by Country (2023-2028)
• 7.4 Germany
• 7.5 France
• 7.6 U.K.
• 7.7 Italy
• 7.8 Russia
• 7.9 Nordic Countries

8 Asia-Pacific

• 8.1 Asia-Pacific Ulcerative Colitis Medicine Market Size (2017-2028)
• 8.2 Asia-Pacific Ulcerative Colitis Medicine Market Size by Country (2017-2022)
• 8.3 Asia-Pacific Ulcerative Colitis Medicine Market Size by Country (2023-2028)
• 8.4 China
• 8.5 Japan
• 8.6 South Korea
• 8.7 Southeast Asia
• 8.8 India
• 8.9 Australia

9 Latin America

• 9.1 Latin America Ulcerative Colitis Medicine Market Size (2017-2028)
• 9.2 Latin America Ulcerative Colitis Medicine Market Size by Country (2017-2022)
• 9.3 Latin America Ulcerative Colitis Medicine Market Size by Country (2023-2028)
• 9.4 Mexico
• 9.5 Brazil

10 Middle East & Africa

• 10.1 Middle East & Africa Ulcerative Colitis Medicine Market Size (2017-2028)
• 10.2 Middle East & Africa Ulcerative Colitis Medicine Market Size by Country (2017-2022)
• 10.3 Middle East & Africa Ulcerative Colitis Medicine Market Size by Country (2023-2028)
• 10.4 Turkey
• 10.5 Saudi Arabia
• 10.6 UAE

11 Key Players Profiles

• 11.1 Sumitomo
• 11.1.1 Sumitomo Company Detail

11.1.2 Sumitomo Business Overview

11.1.3 Sumitomo Ulcerative Colitis Medicine Introduction

11.1.4 Sumitomo Revenue in Ulcerative Colitis Medicine Business (2017-2022)

11.1.5 Sumitomo Recent Development

11.2 Pfizer

11.2.1 Pfizer Company Detail

11.2.2 Pfizer Business Overview

11.2.3 Pfizer Ulcerative Colitis Medicine Introduction

11.2.4 Pfizer Revenue in Ulcerative Colitis Medicine Business (2017-2022)

11.2.5 Pfizer Recent Development

11.3 Novartis

11.3.1 Novartis Company Detail

11.3.2 Novartis Business Overview

11.3.3 Novartis Ulcerative Colitis Medicine Introduction

11.3.4 Novartis Revenue in Ulcerative Colitis Medicine Business (2017-2022)

11.3.5 Novartis Recent Development

11.4 Merck

11.4.1 Merck Company Detail

11.4.2 Merck Business Overview

11.4.3 Merck Ulcerative Colitis Medicine Introduction

11.4.4 Merck Revenue in Ulcerative Colitis Medicine Business (2017-2022)

11.4.5 Merck Recent Development

11.5 Sanofi

11.5.1 Sanofi Company Detail

11.5.2 Sanofi Business Overview

11.5.3 Sanofi Ulcerative Colitis Medicine Introduction

11.5.4 Sanofi Revenue in Ulcerative Colitis Medicine Business (2017-2022)

11.5.5 Sanofi Recent Development

11.6 Johnson and Johnson

11.6.1 Johnson and Johnson Company Detail

11.6.2 Johnson and Johnson Business Overview

11.6.3 Johnson and Johnson Ulcerative Colitis Medicine Introduction

11.6.4 Johnson and Johnson Revenue in Ulcerative Colitis Medicine Business (2017-2022)

11.6.5 Johnson and Johnson Recent Development

11.7 GSK

11.7.1 GSK Company Detail

11.7.2 GSK Business Overview

11.7.3 GSK Ulcerative Colitis Medicine Introduction

11.7.4 GSK Revenue in Ulcerative Colitis Medicine Business (2017-2022)

11.7.5 GSK Recent Development

11.8 AstraZeneca

11.8.1 AstraZeneca Company Detail

11.8.2 AstraZeneca Business Overview

11.8.3 AstraZeneca Ulcerative Colitis Medicine Introduction

11.8.4 AstraZeneca Revenue in Ulcerative Colitis Medicine Business (2017-2022)

11.8.5 AstraZeneca Recent Development

11.9 Cipla

11.9.1 Cipla Company Detail

11.9.2 Cipla Business Overview

11.9.3 Cipla Ulcerative Colitis Medicine Introduction

11.9.4 Cipla Revenue in Ulcerative Colitis Medicine Business (2017-2022)

11.9.5 Cipla Recent Development

11.10 Sun Pharm

11.10.1 Sun Pharm Company Detail

11.10.2 Sun Pharm Business Overview

11.10.3 Sun Pharm Ulcerative Colitis Medicine Introduction

11.10.4 Sun Pharm Revenue in Ulcerative Colitis Medicine Business (2017-2022)

11.10.5 Sun Pharm Recent Development

11.11 Allergan

11.11.1 Allergan Company Detail

11.11.2 Allergan Business Overview

11.11.3 Allergan Ulcerative Colitis Medicine Introduction

11.11.4 Allergan Revenue in Ulcerative Colitis Medicine Business (2017-2022)

11.11.5 Allergan Recent Development

11.12 Teva Pharmaceutical

11.12.1 Teva Pharmaceutical Company Detail

11.12.2 Teva Pharmaceutical Business Overview

11.12.3 Teva Pharmaceutical Ulcerative Colitis Medicine Introduction

11.12.4 Teva Pharmaceutical Revenue in Ulcerative Colitis Medicine Business (2017-2022)

11.12.5 Teva Pharmaceutical Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

• 13.1 Research Methodology
• 13.1.1 Methodology/Research Approach

13.1.2 Data Source

13.2 Disclaimer

Industry Insights
The global Ulcerative Colitis Medicine market size is projected to reach US$ million by 2028, from US$ million in 2021, at a CAGR of % during 2022-2028.

Fully considering the economic change by this health crisis, 5-Aminosalicylic Acid accounting for % of the Ulcerative Colitis Medicine global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While Ulcerative Proctitis segment is altered to an % CAGR throughout this forecast period.

China Ulcerative Colitis Medicine market size is valued at US$ million in 2021, while the North America and Europe Ulcerative Colitis Medicine are US$ million and US$ million, severally. The proportion of the North America is % in 2021, while China and Europe are % and respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period 2022-2028. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Ulcerative Colitis Medicine landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period 2022-2028.

With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Ulcerative Colitis Medicine market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Ulcerative Colitis Medicine market in terms of revenue.

Overall, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Ulcerative Colitis Medicine market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Ulcerative Colitis Medicine market.

Impact of Covid-19 Outbreak

This section of the report has explored the overall status of the Covid scenario and has offered valuable insights into the changes in supply chain disruption, fluctuations in demand, etc. The analysts have also focused on the key measures that the companies are opting to withstand the harsh scenario.

Segmental Analysis

The report has been segmented into product and application segments. The researchers have documented all the products present today in the Ulcerative Colitis Medicine market. They have also shed light on the new product innovations and launches by the key players. In the segmental analysis, the analysts have provided revenue forecast figures based on type and application for the period 2017-2028. They have also discussed about the growth rate and potential of each segment for the period 2017-2028.

Ulcerative Colitis Medicine Breakdown Data by Type

5-Aminosalicylic Acid

Corticosteroids

Immunomodulator Drugs

Biologics

Ulcerative Colitis Medicine Breakdown Data by Application

Ulcerative Proctitis

Proctosigmoiditis

Left-Sided Colitis

Pancolitis

Acute Severe Ulcerative Colitis

Regional Analysis

North America

United States

Canada

Europe

Germany

France

UK

Italy

Russia

Nordic Countries

Rest of Europe

Asia-Pacific

China

Japan

South Korea

Southeast Asia

India

Australia

Rest of Asia

Latin America

Mexico

Brazil

Rest of Latin America

Middle East & Africa

Turkey

Saudi Arabia

UAE

Rest of MEA

Competitive Landscape

This segment focuses on the key players operating in the industry. It underlines all the current and future activities by the prominent manufacturers. By understanding various initiatives being taken up by different players, readers will gain the ability to settle on correct business choices. The authors of the report have provided accurate revenue figures of the companies for the period 2017-2022. The clients are sure to gain the upper hand once they get hold of this report. Key players studied in the research report include:

Sumitomo

Pfizer

Novartis

Merck

Sanofi

Johnson and Johnson

GSK

AstraZeneca

Cipla

Sun Pharm

Allergan

Teva Pharmaceutical

Frequently Asked Questions

What factors will challenge the Ulcerative Colitis Medicine market growth?

Which end-use segment will expand at the fastest CAGR in the Ulcerative Colitis Medicine market?

Which are the emerging players in the Ulcerative Colitis Medicine market?

How concentrated is the Ulcerative Colitis Medicine market?

Which factors are positively contributing to the Ulcerative Colitis Medicine market growth?

Which are the novel product innovations in the Ulcerative Colitis Medicine market?

Which product segment will emerge as the most lucrative in the Ulcerative Colitis Medicine market?

Which factors are increasing the competition in the Ulcerative Colitis Medicine market?

Which are the strategic measures taken by the Ulcerative Colitis Medicine industry players?

Which region will witness inactive growth during the forecast period?

What key trends are likely to emerge in the Ulcerative Colitis Medicine market in the coming years?